Analyst Price Target is $141.33
▲ +27.59% Upside Potential
This price target is based on 13 analysts offering 12 month price targets for Natera in the last 3 months. The average price target is $141.33, with a high forecast of $160.00 and a low forecast of $90.00. The average price target represents a 27.59% upside from the last price of $110.77.
Current Consensus is
The current consensus among 13 contributing investment analysts is to buy stock in Natera. This Buy consensus rating has held steady for over two years.
Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The firm also offers Constellation, a cloud-based software product that allows laboratory customers to gain access to the algorithms and bioinformatics in order to validate and launch tests based on the technology. The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in San Carlos, CA.